• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Endocrinology

Glucagon-like peptide-1 receptor agonists associated with lower depression risk in older adults with diabetes

byAdrian WongandThomas Su
February 24, 2025
in Endocrinology, Pharma, Psychiatry
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this target trial emulation, glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk of depression compared with dipeptidyl peptidase-4 inhibitors among older patients with type 2 diabetes.

2. GLP-1RAs were associated with a similar reduction in risk of depression compared with sodium-glucose cotransporter-2 inhibitors.

Evidence Rating Level: 2 (Good)

Study Rundown: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been associated with various effects in treating type 2 diabetes (T2D), including cardiorenal benefits and weight loss. They are known to cross the blood-brain barrier and exert central dopaminergic effects, which raises concerns that they may also give rise to psychological harms such as depression and suicidality. Although pre-clinical studies suggest that GLP-1RAs may have antidepressant effects, population-based studies have shown mixed results. This study aimed to determine the risk of depression in older adults with diabetes on GLP-1RAs compared with sodium-glucose cotransporter-2 inhibitors (SGLT2is) and dipeptidyl peptidase-4 inhibitors (DPP4is). It was found that GLP-1RAs were not associated with a significant change in risk of depression compared with SGLT2is. However, GLP-1RAs were associated with a one-tenth reduction in depression risk compared with DPP4is. Notably, subgroup analyses showed that the risk of incident depression among patients on GLP-1RAs decreased with longer treatment duration compared with both SGLT2is and DPP4is. The generalizability of this study was limited by its broad patient inclusion criteria; the possibility of unmeasured confounding; the relatively short median follow-up; and its focus on older adults. Nevertheless, this study suggested that GLP-1RAs could have antidepressant effects, particularly with longer treatment durations, thus making them a potential tool for treating diabetes in those at risk for depression.

Click to read the study in AIM

Relevant Reading: Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review

RELATED REPORTS

Semaglutide improves walking ability in patients with peripheral artery disease and type 2 diabetes

#VisualAbstract: Tirzepatide Superior to Semaglutide in Obese Adults Without Diabetes

Calorie restriction and low-fat diets may reduce depression in individuals with higher cardiometabolic risk

In-Depth [retrospective cohort]: This target trial emulation investigated the risk for depression among older patients initiating GLP-1RA treatment compared with SGLT2is and DPP4is. Inclusion criteria were patients aged 66 years or older newly beginning treament with GLP-1RAs, SGLT2is, or DPP4is. Exclusion criteria included diagnosis of type 1 diabetes; end-stage renal disease or dialysis; preexisting depression or other mood disorders; use of antidepressants within 1 year prior to treatment initiation; and concomitant use of GLP-1RAs and control medications. After propensity score matching, risk for incident depression over time was calculated using Kaplan-Meier plots. A total of 14,665 pairs of patients were generated for comparing GLP-1RAs with SGLT2is, and 13,711 pairs were generated for comparing GLP-1RAs with DPP4is. In the GLP-1RA versus SGLT2i cohort, 961 GLP-1RA users and 902 SGLT2i users developed depression, yielding incidence rates of 49.02 and 45.54 per 1000 person-years for GLP-1RA and SGLT2i, respectively (rate difference, 3.48 per 1000 person-years [95% CI, -0.81 to 7.78]; hazard ratio [HR], 1.07 [95% CI, 0.98 to 1.18]). In the GLP-1RA versus DPP4i cohort, 963 GLP-1RA users and 1075 SGLT2i users developed depression, yielding incidence rates of 51.39 and 57.17 per 1000 person-years for GLP-1RA and SGLT2i, respectively (rate difference, -5.78 per 1000 person-years [95% CI, -10.49 to -1.07]; HR, 0.90 [95% CI, 0.82 to 0.98]). Within the subgroup analyses, patients on GLP-1RAs with longer treatment durations were associated with lower incident depression risk compared with both SGLT2is (HR for <0.5 years, 1.18 [95% CI, 1.04 to 1.33]; HR for ≥1 year, 0.84 [95% CI, 0.71 to 1.00]) and DPP4is (HR for <0.5 years, 1.08 [95% CI, 0.96 to 1.22]; HR for ≥1 year, 0.70 [95% CI, 0.59 to 0.82]). Overall, this study suggested that GLP1-RAs may have a similar effect on depression risk compared with SGLT2is, with a potential increase in effectiveness with longer treatment durations.

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: depressiondiabetes mellitusglucagon-like peptide-1 (GLP-1) receptor agonistsobesityolder adultsType 2 Diabetes Mellitus
Previous Post

Ipilimumab/Nivolumab versus Nivolumab in Melanoma Brain Metastases

Next Post

Levothyroxine supplementation in pregnancy not linked to prematurity risk

RelatedReports

Increased number of daily steps linked with decreased mortality in older women
Chronic Disease

Semaglutide improves walking ability in patients with peripheral artery disease and type 2 diabetes

May 29, 2025
#VisualAbstract: Tirzepatide Superior to Semaglutide in Obese Adults Without Diabetes
StudyGraphics

#VisualAbstract: Tirzepatide Superior to Semaglutide in Obese Adults Without Diabetes

May 20, 2025
Vegetarian diet may lower incidence of colorectal cancer
Psychiatry

Calorie restriction and low-fat diets may reduce depression in individuals with higher cardiometabolic risk

May 20, 2025
Food environment associated with gestational diabetes
Pharma

Eli Lilly Takes Legal Action Against Telehealth Startups

May 15, 2025
Next Post
Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity

Levothyroxine supplementation in pregnancy not linked to prematurity risk

Prevalence of common chronic conditions in Medicare Advantage and traditional Medicare beneficiaries

Strict tobacco licensing laws linked to reduced adolescent smoking initiation

Characterization of increased cryptogenic ischemic stroke risk from smoking

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravenous hydrocortisone may reduce risk of kidney failure in patients with sepsis
  • Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension
  • Oral semaglutide reduces cardiovascular event rates in high-risk patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.